Significant Vendor (Details Textual) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Mar. 31, 2017 |
Mar. 31, 2016 |
Jun. 30, 2015 |
Jun. 30, 2016 |
|
| Significant Vendor [Line Items] | ||||||
| Accounts Payable, Current | $ 1,391,000 | $ 1,391,000 | $ 1,177,000 | |||
| Accrued Liabilities, Current | 957,000 | 957,000 | 920,000 | |||
| Research and Development Expense | 1,136,000 | $ 1,048,000 | 3,005,000 | $ 2,303,000 | ||
| Revenue, Net, Total | 37,000 | 379,000 | 247,000 | 673,000 | ||
| Amended Agreement [Member] | ||||||
| Significant Vendor [Line Items] | ||||||
| Research and Development Expense | $ 2,100,000 | |||||
| Revenue, Net, Total | 0 | 357,000 | 137,000 | 635,000 | ||
| Fraunhofer [Member] | ||||||
| Significant Vendor [Line Items] | ||||||
| Accounts Payable, Current | 75,000 | 75,000 | 341,000 | |||
| Accrued Liabilities, Current | 0 | 0 | 122,000 | |||
| Novici [Member] | ||||||
| Significant Vendor [Line Items] | ||||||
| Accounts Payable, Current | 199,000 | 199,000 | $ 200,000 | |||
| Research and Development Expense | $ 225,000 | $ 244,000 | $ 670,000 | $ 723,000 | ||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|